Viracta Therapeutics (Viracta Therapeutics) Debt-to-EBITDA : -0.58 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Viracta Therapeutics Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Viracta Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $18.86 Mil. Viracta Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.00 Mil. Viracta Therapeutics's annualized EBITDA for the quarter that ended in Mar. 2024 was $-32.69 Mil. Viracta Therapeutics's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was -0.58.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Viracta Therapeutics's Debt-to-EBITDA or its related term are showing as below:

VIRX' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.55 Med: -0.42 Max: -0.05
Current: -0.43

During the past 4 years, the highest Debt-to-EBITDA Ratio of Viracta Therapeutics was -0.05. The lowest was -0.55. And the median was -0.42.

VIRX's Debt-to-EBITDA is ranked worse than
100% of 279 companies
in the Biotechnology industry
Industry Median: 1.43 vs VIRX: -0.43

Viracta Therapeutics Debt-to-EBITDA Historical Data

The historical data trend for Viracta Therapeutics's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viracta Therapeutics Debt-to-EBITDA Chart

Viracta Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Debt-to-EBITDA

-0.33

-0.05

-0.52

-0.55

Viracta Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-EBITDA	Get a 7-Day Free Trial												-0.57	-0.56	-0.56	-0.50	-0.58

Competitive Comparison of Viracta Therapeutics's Debt-to-EBITDA

For the Biotechnology subindustry, Viracta Therapeutics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Viracta Therapeutics's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Viracta Therapeutics's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Viracta Therapeutics's Debt-to-EBITDA falls into.

Viracta Therapeutics Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Viracta Therapeutics's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(25.556	+	0)	/	-46.862
	=	-0.55

Viracta Therapeutics's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(18.857	+	0)	/	-32.692
	=	-0.58

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.

Viracta Therapeutics (NAS:VIRX) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Viracta Therapeutics Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Viracta Therapeutics's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Viracta Therapeutics (Viracta Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viracta Therapeutics Inc (NAS:VIRX) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

RYIS:Germany

Address

2533 South Coast Highway 101, Suite 210, Cardiff, CA, USA, 92007

Website

https://www.viracta.com

Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. Its lead product candidate is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people who have received organ transplants.

Executives

Mark Rothera	director, officer: President and CEO	C/O AEGERION PHARMACEUTICALS, INC., 101 MAIN STREET, SUITE 1850, CAMBRIDGE MA 02142
Daniel R. Chevallard	officer: Chief Executive Officer	C/O REGULUS THERAPEUTICS INC., 10614 SCIENCE CENTER DRIVE, SAN DIEGO CA 92121
Darrel P. Cohen	officer: Chief Medical Officer	C/O VIRACTA THERAPEUTICS, INC., 2533 S. COAST HWY 101, SUITE 210, CARDIFF CA 92007
Lisa Rojkjaer	officer: Chief Medical Officer	C/O VIRACTA THERAPEUTICS, INC., 2533 SOUTH COAST HWY., STE. 210, CARDIFF CA 92007
Ivor Royston	director, officer: CEO & President	4401 WILSHIRE BLVD., SUITE 200, LOS ANGELES CA 90010
Jane Chung	director	C/O SUTRO BIOPHARMA, INC., 310 UTAH AVE., SUITE 150, SOUTH SAN FRANCISCO CA 94080
Jane F Barlow	director	6800 BROKEN SOUND PARKWAY NW, 3RD FLOOR, BOCA RATON FL 33487
Flavia Borellini	director	C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063
Barry J. Simon	director	2533 SOUTH COAST HIGHWAY 101, SUITE 210, CARDIFF-BY-THE-SEA CA 92007
Stephen Rubino	director	C/O VIRACTA THERAPEUTICS, INC., 2533 SOUTH COAST HWY., STE. 210, CARDIFF CA 92007
Gur Roshwalb	director, 10 percent owner	C/O CELSUS THERAPEUTICS PLC, 24 WEST 40TH STREET, NEW YORK NY 10018
Roger Pomerantz	director	711 HARVEST HILL ROAD, CHALFONT PA 18914
Michael Huang	director	C/O FREQUENCY THERAPEUTICS, INC., 19 PRESIDENTIAL WAY, 2ND FLOOR, WOBURN MA 01801
Amoon Growth Fund Limited Partnership	10 percent owner	34 YERUSHALAYIM RD., RAANANA L3 4350110
Thomas E Darcy	director	C/O SCIENCE APPLICATIONS INTL CORP, 10260 CAMPUS POINT DR., SAN DIEGO CA 92121